| Diagnostic Yeld of Ultrathin Bronchoscopy in Peripheral Pulmonary Lesions (NCT05526573) | Azienda Sanitaria-Universitaria Integrata di Udine | 2022-07-14 |
| Radiomics Combined With Frozen Section Prediction Model for Spread Through Air Space in Lung Adenocarcinoma (NCT05400304) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2022-07-01 |
| Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection (NCT05517811) | University of Colorado, Denver | 2022-06-26 |
| The Effect of Interventional Pulmonary Rehabilitation Exercise With Advanced Lung Cancer. (NCT05279521) | National Taiwan University Hospital | 2022-03-20 |
| Intraoperative Frozen Section Pathology to Guide Surgical Treatment for Lung Adenocarcinoma (ECTOP-1016) (NCT05794724) | Fudan University | 2022-01-01 |
| Intraoperative Frozen Section Pathology to Diagnose the IASLC Grades for Lung Adenocarcinoma (ECTOP-1014) (NCT05794698) | Fudan University | 2022-01-01 |
| Intraoperative Frozen Section Pathology to Guide Surgical Treatment for Lung Adenocarcinoma (ECTOP-1015) (NCT05794711) | Fudan University | 2022-01-01 |
| Milademetan in Advanced/Metastatic Solid Tumors (NCT05012397) | Rain Oncology Inc | 2021-11-01 |
| Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model (NCT05136014) | Central Hospital, Nancy, France | 2021-11-01 |
| Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT) (NCT04965831) | Tianjin Medical University Cancer Institute and Hospital | 2021-08-01 |
| IBI188 Combination Therapy in Solid Tumors (NCT04861948) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-05-25 |
| Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) (NCT04625647) | SWOG Cancer Research Network | 2021-04-16 |
| Cios Mobile 3D Spin for Robotic Bronchoscopy (NCT04740047) | Mayo Clinic | 2021-02-01 |
| Plasma Exosomes Reveal the Efficacy of Targeted Therapy in Patients With EGFR Mutation in Lung Adenocarcinoma (NCT06730477) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2021-01-01 |
| A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (NCT04682431) | Ikena Oncology | 2020-11-10 |
| A Study of PY314 in Subjects With Advanced Solid Tumors (NCT04691375) | Ikena Oncology | 2020-10-29 |
| TCM in the Treatment of Lung Adenocarcinoma (NCT04482829) | Henan University of Traditional Chinese Medicine | 2020-09-15 |
| Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma (NCT04339218) | Institut Bergonié | 2020-08-28 |
| 18F-FDG and 68Ga-FAPI PET/CT in Lung Adenocarcinoma (NCT04588064) | The First Affiliated Hospital of Xiamen University | 2020-07-01 |
| Identify Prognostic Biomarkers of Lung Cancer (NCT05010330) | RenJi Hospital | 2020-07-01 |
| Radiomics-based Prediction Model of Tumor Spread Through Air Space in Lung Adenocarcinoma (NCT04893200) | University of Roma La Sapienza | 2020-02-01 |
| Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers (NCT06255197) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2019-11-04 |
| Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm (NCT04937283) | Shanghai Pulmonary Hospital, Shanghai, China | 2019-10-01 |
| Comparison of Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm (NCT05838053) | Shanghai Pulmonary Hospital, Shanghai, China | 2019-08-20 |
| Bevacizumab and Radiotherapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver Gene (NCT03905317) | Sun Yat-sen University | 2019-03-01 |
| A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma (NCT03891173) | Helix BioPharma Corporation | 2019-02-19 |
| Derivation and Validation of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules (NCT04554875) | Shanghai Pulmonary Hospital, Shanghai, China | 2019-01-01 |
| Bevacizumab After Chemoradiotherapy For Locally Advanced Lung Adenocarcinoma (NCT03904563) | Sun Yat-sen University | 2019-01-01 |
| Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation (NCT03486496) | Fujian Cancer Hospital | 2018-06-05 |
| Lung Nodule Prospective Database (NCT03922828) | Singapore General Hospital | 2018-05-01 |
| Exhaled Breath Particles in Lung Cancer (NCT05395611) | Lund University Hospital | 2018-01-23 |
| Sleep State in Lung Cancer: A Retrospective Analysis (NCT06953492) | Shanghai Zhongshan Hospital | 2018-01-01 |
| Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer (NCT03391869) | M.D. Anderson Cancer Center | 2017-12-29 |
| Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma (NCT03376737) | Henan Cancer Hospital | 2017-10-12 |
| CAR T Cells in Mesothelin Expressing Cancers (NCT03054298) | University of Pennsylvania | 2017-04-06 |
| A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib (NCT03076164) | Memorial Sloan Kettering Cancer Center | 2017-03-01 |
| Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial (NCT02951637) | Shanghai Chest Hospital | 2016-12-01 |
| Chemoresistance and Involvement of the NOTCH Pathway in Patients With Lung Adenocarcinoma (NCT02898857) | University Hospital, Montpellier | 2016-09-01 |
| Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy (NCT02787447) | First People's Hospital of Hangzhou | 2016-05-01 |
| A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy (NCT02788058) | First People's Hospital of Hangzhou | 2016-05-01 |
| Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib (NCT02759835) | National Cancer Institute (NCI) | 2016-04-13 |
| Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation (NCT02737774) | Henan Cancer Hospital | 2016-04-13 |
| A Study to Predict Gefitinib' s Efficacy for Lung Cancer by Plasma Free Nucleic Acids EGFR Gene Mutation Test (NCT02738684) | Southwest Hospital, China | 2016-04-01 |
| Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR (NCT02691871) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2016-02-01 |
| Pemetrexed and Platinum Use in the Neoadjuvant Setting for Resectable Stage II and IIIA Lung Adenocarcinoma (ECTOP-1002) (NCT02980991) | Fudan University | 2015-12-01 |
| Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma (NCT02621333) | Henan Cancer Hospital | 2015-10-01 |
| Vitamin Supplementation in NSCLC Patients on Pemetrexed Based Chemotherapy (NCT02679443) | Post Graduate Institute of Medical Education and Research, Chandigarh | 2015-07-01 |
| EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression (NCT03544814) | Shanghai Chest Hospital | 2015-01-01 |
| A Study Examining Maintenance Bevacizumab (Avastin®) Monotherapy in Participants With Advanced Lung Adenocarcinoma (NCT02093000) | Hoffmann-La Roche | 2014-11-30 |
| Blood Detection of EGFR Mutation For Iressa Treatment (NCT02282267) | Peking University Cancer Hospital & Institute | 2014-10-01 |
| Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer (NCT02186847) | NRG Oncology | 2014-08-01 |
| Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer (NCT01737502) | Mayo Clinic | 2014-05-14 |
| Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in Early Stage Lung Cancer Patients and Assessing the Disease-free Survival With Long-term Follow-up (NCT02121925) | Myriad Genetic Laboratories, Inc. | 2014-05-01 |
| Molecular Analysis of 150 Lung Adenocarcinoma (NCT02843711) | Hospices Civils de Lyon | 2014-01-01 |
| Comparison of cVATS Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion (NCT02011997) | The First Affiliated Hospital of Guangzhou Medical University | 2013-12-01 |
| Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas (NCT01942629) | Rambam Health Care Campus | 2013-10-01 |
| Whole-Exome Sequencing (WES) of Cancer Patients (NCT02127359) | Dana-Farber Cancer Institute | 2012-09-01 |
| Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma. (NCT01578551) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2012-05-01 |
| Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases (NCT01578668) | Guangzhou Medical University | 2012-01-01 |
| Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (NCT01386385) | National Cancer Institute (NCI) | 2011-06-20 |
| MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy (NCT01294306) | National Cancer Institute (NCI) | 2011-02-01 |
| Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma (NCT01249066) | China Medical University Hospital | 2010-09-01 |
| Expression of Optic Atrophy Type 1 (OPA1) Protein in Lung Adenocarcinoma (NCT01249053) | China Medical University Hospital | 2010-08-01 |
| Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (NCT00955305) | National Cancer Institute (NCI) | 2010-03-01 |
| Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (NCT00334815) | National Cancer Institute (NCI) | 2006-06-15 |
| Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer (NCT00950365) | Albert Einstein College of Medicine | 2006-04-01 |
| Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer (NCT00126581) | National Cancer Institute (NCI) | 2005-08-15 |